Health & Medicine
-
First-of-its-kind AstraZeneca Drug Cuts Risk of Severe COVID-19 by 50%
AstraZeneca company announced on Monday the results of its Phase III COVID-19 treatment trial which showed that their antibody drug is the first of its kind to both prevent and treat COVID-19, and cut the risk of severe COVID-19 by at least 50 percent.
Latest Research Articles
-
Experts Debunked Fears of Mega-Tsunami Coming to East Coast Due to La Palma Volcanic Eruption
Rare Snow Leopard in South Dakota Zoo Succumbs to Suspected COVID-19 After Breathing Problems
-
Experts Warn Ominous Threat of Flu Season to Happen this Year, But is US Ready?
-
Extreme Weather Casualty Rates are Going Down, But Global Warming May Change That
-
What Makes Us Human? This Often Overlooked DNA May Provide Answers
-
Study: 6 Million Americans Felt no Significant Side Effects From mRNA Vaccines
-
87 Ultramarathoners Rescued From Near-Whiteout Blizzard-Like Experience in Utah
-
Hair Transplant in Turkey - Is It a Good Choice for Hair Restoration?
-
Oil Spill Investigators Claimed that Pipeline Damage may Have Happened Months Before
-
'Historic Day': WHO Initiates Widespread Rollout of First-Ever Malaria Vaccine in Africa
-
UK Public Now Consume Less Meat to Improve Food Sustainability
-
No Vaccine, No Organ! Unvaccinated Patients Denied Organ Transplants in US Hospital
MOST POPULAR
-
Spectacular Northern Lights Show Possible in 10 States as Geomagnetic Storm Approaches
-
Earth's Magnetic North Pole Shifts Toward Russia, Scientists Update Its Location
-
Mount Rainier's Volcanic Activity Closely Watched by Scientists
-
Chinese Astronauts Create Oxygen and Rocket Fuel Using Artificial Photosynthesis in Space
-
Meet Romulus and Remus: Dire Wolf Pups Resurrected with Ancient DNA, Thanks to Colossal Biosciences
